Skip to main content

WCG Launches 360 Protocol Assessment™ Solution to Ensure Protocol Quality by Design

Princeton, N.J. – May 9, 2023 – WCG, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today launched 360 Protocol Assessment™, an integrated, turn-key solution that addresses ICH E8 R1 expectations and improves clinical trial predictability by providing sponsors with an operational risk and feasibility assessment of the protocol through the lens of multi-functional stakeholders. This process decreases the number of required protocol amendments and highlights key risks and mitigations during the planning phase of the trial.

The 360 Protocol Assessment™ provides a holistic view of a sponsor’s protocol to ensure quality by design. WCG’s quality, operations, and diversity, equity and inclusion subject matter experts identify potential areas of risk in conjunction with its vast network of investigators, sites, and patient advocacy groups to ensure all key stakeholder input is received. The assessment incorporates strategies to proactively mitigate or manage the identified risks for faster clinical trial execution. Finally, through WCG Data Intelligence, the company provides deep insights into the competitive landscape of the protocol being reviewed that can be leveraged for site selection.

“Through this exciting new solution, WCG offers insight and pressure-test protocols for risk from the very beginning,” explains Christine Albano, general manager of Benchmarking and Analytics, WCG Research Solutions. “We can reduce uncertainty in study start-up activities, identify site readiness, flag any potential obstacles to patient recruitment, and take a more proactive approach to diversity and inclusion planning.”

“Protocol amendments have long been a challenge for the drug development industry given their impact on clinical trial timelines and costs,” adds Terri Moench, president, WCG Clinical Research Solutions. “According to a 2021 Tufts Center for the Study of Drug Development survey, nearly eight of 10 phase II protocols and seven of 10 phase III protocols have at least one substantial protocol amendment. Tufts CSDD estimates that sponsors are spending $7 to $8 billion annually to implement protocol amendments. Making the investment in a protocol optimization solution like this is key to conducting faster, higher-quality clinical trials.”

To learn more about WCG’s 360 Protocol Assessment™, click here.

About WCG

WCG is a global leader of solutions that measurably improve and accelerate clinical research. Biopharmaceutical and medical device companies, contract research organizations (CROs), research institutions, and sites partner with us for our unmatched expertise, data intelligence, and purpose-built technology to make informed decisions and optimize study outcomes, while maintaining the highest standards of human participant protection. WCG raises the bar by pioneering new concepts, reimagining processes, fostering compliance and safety, and empowering those who perform clinical trials to accelerate the delivery of medical therapies and devices that improve lives. For more information, please visit or follow us on LinkedIn or X @WCGClinical.

Maximize your investment: schedule a trial design and protocol planning consultation

When you have our experts review your protocol, the early investment ensures your study—and overall investment—meets its full potential. To start, simply fill out the form.